Verhoef LM, et al. - Researchers identified the factors that play a role for patients with RA when considering dose reduction (ie, gradual tapering until discontinuation) of biological DMARDs (bDMARDs). They also determined their relative importance. Implementation of bDMARD dose reduction was facilitated by the results from this study. The care providers are informed about what is important for patients and a basis for shared decision making is provided. The opinion of the rheumatologist was valued by the patients, and being involved in the decision to start tapering was highly ranked as well.